Drug Trial Radar · NCT04367883
Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
Last checked: Nov 20, 2026Latest source record: Mar 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,000
Planned (sponsor's estimate)
Start
Mar 1, 2020
Primary completion
Jan 19, 2025
Study completion Feb 24, 2028
Sponsor
- Lead sponsor
- Consorci Sanitari de TerrassaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina; Institut Català de la Salut
- First posted
- Apr 29, 2020
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection. Other authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease. The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.
Conditions
- COVID19
- Influenza Vaccination
- ACE Inhibitors
- ARB
- Antihistamine Allergy
- Amantadine
Interventions
AntihistamineDrug
No intervention is performed. We propose an observational study.
AmantadineDrug
No intervention is performed. We propose an observational study
ACEIDrug
No intervention is performed. We propose an observational study.
ARBDrug
No intervention is performed. We propose an observational study.
Influenza vaccine and COVIDOther
No intervention is performed. We propose an observational study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- hospital outputTime frame: from March 1, 2020.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hospital de Terrassa
Terrassa, Barcelona, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.